China-based Jemincare group announced on Monday that it has completed a phase one clinical trial of a self-developed novel coronavirus specific neutralising antibody (Project code: JMB2002).

The company started the clinical trial of JMB2002 in January 2021.

The study is a single-centre, randomized, double-blind, placebo-controlled, single-dose escalation phase I trial studying JMB2002's tolerability, safety, pharmacokinetic characteristics and immunogenicity in healthy patients. It enrolled 40 patients in four dose groups from low to high. All patients have completed the whole trial.

The study revealed that only one patient underwent grade 2 adverse events regarding the study drug. The other grade 2 adverse events were all grade 1 and all grade 2 adverse events were in remission or completely recovered, while no patients underwent any serious adverse events regarding the study drug.